BR112016025427A2 - processos de preparação de um inibidor de jak1 e formas do mesmo - Google Patents
processos de preparação de um inibidor de jak1 e formas do mesmoInfo
- Publication number
- BR112016025427A2 BR112016025427A2 BR112016025427A BR112016025427A BR112016025427A2 BR 112016025427 A2 BR112016025427 A2 BR 112016025427A2 BR 112016025427 A BR112016025427 A BR 112016025427A BR 112016025427 A BR112016025427 A BR 112016025427A BR 112016025427 A2 BR112016025427 A2 BR 112016025427A2
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- forms
- preparing
- jak1 inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
esta invenção refere-se a processos para a preparação de um inibidor de jak1 com a fórmula ia: ia bem como formas do inibidor
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461986789P | 2014-04-30 | 2014-04-30 | |
US201461986738P | 2014-04-30 | 2014-04-30 | |
PCT/US2015/028224 WO2015168246A1 (en) | 2014-04-30 | 2015-04-29 | Processes of preparing a jak1 inhibitor and new forms thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016025427A2 true BR112016025427A2 (pt) | 2017-08-15 |
Family
ID=53264736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016025427A BR112016025427A2 (pt) | 2014-04-30 | 2015-04-29 | processos de preparação de um inibidor de jak1 e formas do mesmo |
Country Status (20)
Country | Link |
---|---|
US (2) | US9802957B2 (pt) |
EP (1) | EP3137471A1 (pt) |
JP (1) | JP2017514832A (pt) |
KR (1) | KR20170007331A (pt) |
CN (1) | CN106687462A (pt) |
AU (1) | AU2015253192B2 (pt) |
BR (1) | BR112016025427A2 (pt) |
CA (1) | CA2947418A1 (pt) |
CL (3) | CL2016002748A1 (pt) |
CR (1) | CR20160553A (pt) |
EA (1) | EA201692193A1 (pt) |
EC (1) | ECSP16088985A (pt) |
IL (1) | IL248542B (pt) |
MA (1) | MA39987A (pt) |
MX (1) | MX2016014192A (pt) |
PE (1) | PE20170300A1 (pt) |
PH (1) | PH12016502177A1 (pt) |
SG (2) | SG11201609016VA (pt) |
TW (1) | TW201625643A (pt) |
WO (1) | WO2015168246A1 (pt) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0619817B8 (pt) | 2005-12-13 | 2021-05-25 | Incyte Corp | composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição |
MX2009013402A (es) | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
EP4036088B1 (en) | 2010-03-10 | 2024-04-03 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
IL291391B (en) | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
WO2014113388A1 (en) | 2013-01-15 | 2014-07-24 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
PT2964650T (pt) | 2013-03-06 | 2019-02-26 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
MX2016001639A (es) | 2013-08-07 | 2016-10-07 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
LT3129021T (lt) | 2014-04-08 | 2020-12-10 | Incyte Corporation | B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu |
AU2015253192B2 (en) | 2014-04-30 | 2019-05-16 | Incyte Holdings Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
JP7089141B2 (ja) | 2016-10-03 | 2022-06-22 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | 新規なjak1選択的阻害剤およびその使用 |
RS61317B1 (sr) * | 2017-01-11 | 2021-02-26 | Leo Pharma As | Novi derivati amino-imidazopiridina kao inhibitori janus kinaze i njihova farmaceutska upotreba |
AU2018290287B2 (en) * | 2017-06-21 | 2024-06-13 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
RS63312B1 (sr) | 2018-01-30 | 2022-07-29 | Incyte Corp | Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on) |
CN111936135A (zh) | 2018-02-16 | 2020-11-13 | 因赛特公司 | 用于治疗细胞因子相关的病症的jak1通路抑制剂 |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
JP2021519772A (ja) | 2018-03-30 | 2021-08-12 | インサイト・コーポレイションIncyte Corporation | 炎症性皮膚疾患のバイオマーカー |
EP3775923A1 (en) | 2018-04-13 | 2021-02-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
WO2020132210A1 (en) | 2018-12-19 | 2020-06-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
EP3934651A1 (en) | 2019-03-05 | 2022-01-12 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
TW202102222A (zh) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
EP3981398A4 (en) * | 2019-06-06 | 2023-03-15 | Hangzhou Highlightll Pharmaceutical Co., Ltd. | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT |
CN113906035B (zh) * | 2019-06-06 | 2023-11-10 | 杭州高光制药有限公司 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
PE20231102A1 (es) | 2020-06-02 | 2023-07-19 | Incyte Corp | Procesos para preparar un inhibidor de jak1 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
KR20230095923A (ko) | 2020-08-18 | 2023-06-29 | 인사이트 코포레이션 | Jak1 억제제를 제조하기 위한 공정 및 중간체 |
PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
AU2021390533A1 (en) | 2020-12-04 | 2023-06-29 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
TW202237089A (zh) | 2020-12-08 | 2022-10-01 | 美商英塞特公司 | 用於治療白斑病之jak1途徑抑制劑 |
US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
WO2023250316A1 (en) * | 2022-06-22 | 2023-12-28 | Ptc Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
US20240058343A1 (en) | 2022-08-05 | 2024-02-22 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
JP2513001B2 (ja) * | 1988-11-01 | 1996-07-03 | 山川薬品工業株式会社 | 光学活性テトラヒドロフラン−2−カルボン酸のラセミ化方法 |
JPH02225463A (ja) * | 1989-02-27 | 1990-09-07 | Nissan Chem Ind Ltd | N―アセチル―インドリン―2―カルボン酸エステルのラセミ化法 |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
JP3178301B2 (ja) * | 1994-08-08 | 2001-06-18 | 東レ株式会社 | ラセミ脂肪族ヘテロ環カルボン酸エステルの製造方法 |
EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2339961C (en) | 1998-08-11 | 2009-01-20 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
BR0111747A (pt) | 2000-06-28 | 2003-07-08 | Smithkline Beecham Plc | Processo de moagem úmida |
AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
AU2002337142B2 (en) | 2001-09-19 | 2007-10-11 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
CN101703509A (zh) | 2001-10-30 | 2010-05-12 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
CA2586605A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
BRPI0619817B8 (pt) | 2005-12-13 | 2021-05-25 | Incyte Corp | composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição |
WO2008011190A1 (en) | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | Cgrp receptor antagonists |
US8338455B2 (en) | 2006-12-20 | 2012-12-25 | Amgen Inc. | Compounds and methods of use |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
MX2009013402A (es) | 2007-06-13 | 2010-02-24 | Incyte Corp | Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EP2220068B1 (en) | 2007-11-16 | 2016-01-27 | Incyte Holdings Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
NZ587928A (en) | 2008-03-11 | 2012-08-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
CA2727928A1 (en) | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
CN102574857B (zh) | 2009-07-08 | 2015-06-10 | 利奥制药有限公司 | 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物 |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
ES2435491T3 (es) | 2009-10-09 | 2013-12-19 | Incyte Corporation | Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
RU2012132278A (ru) | 2010-01-12 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Трициклические гетероциклические соединения, содержащие их композиции и способы их применения |
JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Janusキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
EP4036088B1 (en) | 2010-03-10 | 2024-04-03 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
EP3087972A1 (en) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
CA2818545C (en) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
MY172862A (en) | 2011-03-10 | 2019-12-13 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
KR20150074193A (ko) * | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
IL291391B (en) | 2012-11-15 | 2022-11-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
PT2964650T (pt) | 2013-03-06 | 2019-02-26 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
MX2016001639A (es) | 2013-08-07 | 2016-10-07 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
AR097388A1 (es) * | 2013-08-20 | 2016-03-09 | Incyte Corp | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva |
KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
LT3129021T (lt) | 2014-04-08 | 2020-12-10 | Incyte Corporation | B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu |
AU2015253192B2 (en) | 2014-04-30 | 2019-05-16 | Incyte Holdings Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
-
2015
- 2015-04-29 AU AU2015253192A patent/AU2015253192B2/en not_active Ceased
- 2015-04-29 MX MX2016014192A patent/MX2016014192A/es unknown
- 2015-04-29 PE PE2016002151A patent/PE20170300A1/es unknown
- 2015-04-29 KR KR1020167033696A patent/KR20170007331A/ko unknown
- 2015-04-29 SG SG11201609016VA patent/SG11201609016VA/en unknown
- 2015-04-29 JP JP2016565276A patent/JP2017514832A/ja active Pending
- 2015-04-29 BR BR112016025427A patent/BR112016025427A2/pt not_active Application Discontinuation
- 2015-04-29 MA MA039987A patent/MA39987A/fr unknown
- 2015-04-29 TW TW104113773A patent/TW201625643A/zh unknown
- 2015-04-29 WO PCT/US2015/028224 patent/WO2015168246A1/en active Application Filing
- 2015-04-29 EP EP15724406.2A patent/EP3137471A1/en not_active Withdrawn
- 2015-04-29 SG SG10201809518QA patent/SG10201809518QA/en unknown
- 2015-04-29 CA CA2947418A patent/CA2947418A1/en not_active Abandoned
- 2015-04-29 US US14/699,500 patent/US9802957B2/en active Active
- 2015-04-29 EA EA201692193A patent/EA201692193A1/ru unknown
- 2015-04-29 CN CN201580034662.3A patent/CN106687462A/zh active Pending
- 2015-04-29 CR CR20160553A patent/CR20160553A/es unknown
-
2016
- 2016-10-27 IL IL248542A patent/IL248542B/en active IP Right Grant
- 2016-10-28 CL CL2016002748A patent/CL2016002748A1/es unknown
- 2016-11-02 PH PH12016502177A patent/PH12016502177A1/en unknown
- 2016-11-18 EC ECIEPI201688985A patent/ECSP16088985A/es unknown
-
2017
- 2017-09-22 US US15/712,850 patent/US10450325B2/en active Active
-
2018
- 2018-06-29 CL CL2018001790A patent/CL2018001790A1/es unknown
-
2019
- 2019-07-19 CL CL2019002032A patent/CL2019002032A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20160553A (es) | 2017-04-25 |
WO2015168246A1 (en) | 2015-11-05 |
US20180099978A1 (en) | 2018-04-12 |
KR20170007331A (ko) | 2017-01-18 |
PH12016502177A1 (en) | 2017-02-06 |
CL2018001790A1 (es) | 2018-08-31 |
CL2019002032A1 (es) | 2019-11-29 |
IL248542A0 (en) | 2016-12-29 |
CL2016002748A1 (es) | 2017-05-19 |
US10450325B2 (en) | 2019-10-22 |
EP3137471A1 (en) | 2017-03-08 |
MA39987A (fr) | 2017-03-08 |
CN106687462A (zh) | 2017-05-17 |
US20150344497A1 (en) | 2015-12-03 |
JP2017514832A (ja) | 2017-06-08 |
ECSP16088985A (es) | 2017-02-24 |
SG10201809518QA (en) | 2018-11-29 |
AU2015253192B2 (en) | 2019-05-16 |
IL248542B (en) | 2019-05-30 |
TW201625643A (zh) | 2016-07-16 |
CA2947418A1 (en) | 2015-11-05 |
AU2015253192A1 (en) | 2016-12-01 |
SG11201609016VA (en) | 2016-11-29 |
MX2016014192A (es) | 2017-05-01 |
EA201692193A1 (ru) | 2017-07-31 |
US9802957B2 (en) | 2017-10-31 |
PE20170300A1 (es) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
ECSP17029371A (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CO2017006920A2 (es) | Picolinamidas como fungicidas | |
DOP2016000173A (es) | Heteroarilos y usos de estos | |
BR112017025398A2 (pt) | formas de dosagem sólidas de palbociclib | |
UY36480A (es) | Uso de compuestos de picolinamida como fungicidas | |
CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
BR112016022598A2 (pt) | Formulação de rapamicina inalável para o tratamento de condições relacionadas com a idade | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
TR201906366T4 (tr) | Polisiklik-karbamoilpiridon bileşiklerinin sentezi. | |
ES2897914T8 (es) | Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos | |
CL2016002638A1 (es) | Nuevos inhibidores de la nitrificación | |
DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
BR112016026046A2 (pt) | Uso de compostos de tienotriazolodiazepina | |
EA201790982A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
CO2017001389A2 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
BR112016029510A2 (pt) | métodos para a preparação de um composto, e, composto intermediário. | |
DK3137437T3 (da) | Mikroindkapslet nitrifikationsinhibitorsammensætning | |
CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
ITBA20140018A1 (it) | Macchinario per la produzione di stracciatella | |
BR112016028941A2 (pt) | uso de antiespumantes como aditivos antideriva". | |
PE20180574A1 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
ITUB20156862A1 (it) | Composizioni per il trattamento della psoriasi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |